<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377468</url>
  </required_header>
  <id_info>
    <org_study_id>2310106</org_study_id>
    <secondary_id>Eudra-CT: 2006-000439-85</secondary_id>
    <nct_id>NCT00377468</nct_id>
  </id_info>
  <brief_title>Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study)</brief_title>
  <official_title>Low Dose Administration of Delta9-Tetrahydrocannabinol for the Prevention of Hyperalgesia and Chronic Pain in Patients With Acute Complex Regional Pain Syndrome (CRPS) of the Upper Limb</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Research Network on Neuropathic Pain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether application of low dose
      Delta9-Tetrahydrocannabinol can prevent the development of chronic pain in patients with
      acute CRPS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent animal data suggest that the endocannabinoid system is a promising target in the
      prevention of chronic pain. It has been shown that the endocannabinoid system modifies
      excitatory and inhibitory currents in structures involved in the development of chronic pain
      such as the amygdala.

      CRPS is a neuropathic pain condition, which is known to become chronic in a significant
      percentage. The study compares the effect of low dose Delta9-Tetrahydrocannabinol (90 days)
      and placebo in acute CRPS. All patients will receive a standard treatment consisting of drug
      therapy and physiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2006</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of chronic pain at one year assessed with Visual Analogue Scale (VAS)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in somatosensory phenotype at one year assessed with Quantitative Sensory Testing (QST)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor function of the affected extremity at one year assessed with a biometric evaluation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Health Related Quality of Life at one year assessed with SF-36</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma endocannabinoid levels at 30, 60, 90 days and at one year</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Complex Regional Pain Syndromes</condition>
  <condition>CRPS</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delta9-Tetrahydrocannabinol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical diagnosis of acute CRPS (time from inciting event less than 16
             weeks) of the upper extremity

          -  No risk of dependency in a psychological assessment

        Exclusion Criteria:

          -  History of alcohol or drug abuse

          -  Cardiac arrhythmias

          -  Acute or chronic renal failure

          -  ASA physical status classification III or higher

          -  Psychiatric disorders

          -  Pregnancy and breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahnaz C Azad, MD;PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, Interdisciplinary Pain Clinic Grosshadern, University of Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meike Lauchart, MD</last_name>
    <phone>+49897095</phone>
    <phone_ext>4464</phone_ext>
    <email>Meike.Lauchart@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Volker Huge, MD</last_name>
    <phone>+49897095</phone>
    <phone_ext>4464</phone_ext>
    <email>Volker.Huge@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anesthesiology, Interdisciplinary Pain Clinic Grosshadern, Universitiy of Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.neuro.med.tu-muenchen.de/dfns/</url>
    <description>Homepage of the German Research Network on Neuropathic Pain</description>
  </link>
  <reference>
    <citation>Rolke R, Baron R, Maier C, Tölle TR, Treede RD, Beyer A, Binder A, Birbaumer N, Birklein F, Bötefür IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer GB, Magerl W, Maihöfner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006 Aug;123(3):231-43. Epub 2006 May 11. Erratum in: Pain. 2006 Nov;125(1-2):197.</citation>
    <PMID>16697110</PMID>
  </reference>
  <reference>
    <citation>Azad SC, Monory K, Marsicano G, Cravatt BF, Lutz B, Zieglgänsberger W, Rammes G. Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci. 2004 Nov 3;24(44):9953-61.</citation>
    <PMID>15525780</PMID>
  </reference>
  <reference>
    <citation>Azad SC, Eder M, Marsicano G, Lutz B, Zieglgänsberger W, Rammes G. Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem. 2003 Mar-Apr;10(2):116-28.</citation>
    <PMID>12663750</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2006</study_first_submitted>
  <study_first_submitted_qc>September 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2006</study_first_posted>
  <last_update_submitted>June 26, 2008</last_update_submitted>
  <last_update_submitted_qc>June 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2008</last_update_posted>
  <keyword>THC</keyword>
  <keyword>CRPS</keyword>
  <keyword>Pain</keyword>
  <keyword>Complex Regional Pain Syndrome</keyword>
  <keyword>Neuropathic Pain</keyword>
  <keyword>Chronic</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
    <mesh_term>Complex Regional Pain Syndromes</mesh_term>
    <mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

